41,864 Shares in iRhythm Technologies, Inc. (NASDAQ:IRTC) Bought by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new position in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 41,864 shares of the company's stock, valued at approximately $3,775,000. Susquehanna Fundamental Investments LLC owned about 0.13% of iRhythm Technologies as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of IRTC. Barclays PLC increased its holdings in iRhythm Technologies by 34.3% in the 3rd quarter. Barclays PLC now owns 209,247 shares of the company's stock worth $15,534,000 after purchasing an additional 53,498 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in shares of iRhythm Technologies by 25.6% in the fourth quarter. Stephens Investment Management Group LLC now owns 502,925 shares of the company's stock valued at $45,349,000 after buying an additional 102,600 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in iRhythm Technologies by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 570,048 shares of the company's stock worth $50,991,000 after acquiring an additional 50,075 shares during the last quarter. KBC Group NV increased its position in iRhythm Technologies by 45.1% in the 4th quarter. KBC Group NV now owns 1,319 shares of the company's stock valued at $119,000 after acquiring an additional 410 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of iRhythm Technologies by 23.2% during the fourth quarter. Bank of New York Mellon Corp now owns 491,485 shares of the company's stock valued at $44,317,000 after acquiring an additional 92,591 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group decreased their price target on iRhythm Technologies from $152.00 to $139.00 and set a "buy" rating for the company in a research note on Friday. Truist Financial boosted their price target on shares of iRhythm Technologies from $111.00 to $145.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. StockNews.com upgraded shares of iRhythm Technologies from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Oppenheimer increased their price target on iRhythm Technologies from $105.00 to $120.00 and gave the stock an "outperform" rating in a report on Wednesday, January 8th. Finally, The Goldman Sachs Group upped their target price on iRhythm Technologies from $91.00 to $124.00 and gave the company a "neutral" rating in a research report on Monday, February 24th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.55.

iRhythm Technologies Stock Performance

NASDAQ:IRTC traded up $22.53 during trading hours on Friday, reaching $131.12. The stock had a trading volume of 2,131,857 shares, compared to its average volume of 465,963. iRhythm Technologies, Inc. has a 12-month low of $55.92 and a 12-month high of $139.00. The company has a debt-to-equity ratio of 9.00, a quick ratio of 6.12 and a current ratio of 6.27. The stock has a 50 day simple moving average of $103.78 and a 200 day simple moving average of $95.94. The stock has a market cap of $4.19 billion, a P/E ratio of -36.02 and a beta of 1.45.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.06). iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The business had revenue of $158.68 million for the quarter, compared to analysts' expectations of $153.39 million. During the same quarter in the previous year, the company posted ($1.23) earnings per share. The business's quarterly revenue was up 20.3% compared to the same quarter last year. On average, research analysts forecast that iRhythm Technologies, Inc. will post -1.98 EPS for the current fiscal year.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.